% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Dragomir:277773,
author = {M.-P. Dragomir$^*$ and E. Fuentes-Mattei and M. Winkle and
K. Okubo and R. Bayraktar and E. Knutsen and A. Qdaisat and
M. Chen and Y. Li and M. Shimizu and L. Pang and K. Liu and
X. Liu and S. Anfossi and H. Zhang and I. Koch and A. M.
Tran and S. Mohapatra and A. Ton and M. Kaplan and M. W.
Anderson and S. J. Rothfuss and R. Silasi and R. S. Keshari
and M. Ferracin and C. Ivan and C. Rodriguez-Aguayo and G.
Lopez-Berestein and C. Georgescu and P. P. Banerjee and R.
Basar and Z. Li and D. Horst$^*$ and C. Vasilescu and M. T.
S. Bertilaccio and K. Rezvani and F. Lupu and S.-C. Yeung
and G. A. Calin},
title = {{A}nti-mi{R}-93-5p therapy prolongs sepsis survival by
restoring the peripheral immune response.},
journal = {The journal of clinical investigation},
volume = {133},
number = {14},
issn = {0021-9738},
address = {Ann Arbor, Mich.},
publisher = {ASCJ},
reportid = {DKFZ-2023-01488},
pages = {e158348},
year = {2023},
abstract = {Sepsis remains a leading cause of death for humans and
currently has no pathogenesis-specific therapy. Hampered
progress is partly due to a lack of insight into deep
mechanistic processes. In the past decade, deciphering the
functions of small noncoding miRNAs in sepsis pathogenesis
became a dynamic research topic. To screen for new miRNA
targets for sepsis therapeutics, we used samples for miRNA
array analysis of PBMCs from patients with sepsis and
control individuals, blood samples from 2 cohorts of
patients with sepsis, and multiple animal models: mouse
cecum ligation puncture-induced (CLP-induced) sepsis, mouse
viral miRNA challenge, and baboon Gram+ and Gram- sepsis
models. miR-93-5p met the criteria for a therapeutic target,
as it was overexpressed in baboons that died early after
induction of sepsis, was downregulated in patients who
survived after sepsis, and correlated with negative clinical
prognosticators for sepsis. Therapeutically, inhibition of
miR-93-5p prolonged the overall survival of mice with
CLP-induced sepsis, with a stronger effect in older mice.
Mechanistically, anti-miR-93-5p therapy reduced inflammatory
monocytes and increased circulating effector memory T cells,
especially the CD4+ subset. AGO2 IP in miR-93-KO T cells
identified important regulatory receptors, such as CD28, as
direct miR-93-5p target genes. In conclusion, miR-93-5p is a
potential therapeutic target in sepsis through the
regulation of both innate and adaptive immunity, with
possibly a greater benefit for elderly patients than for
young patients.},
keywords = {Humans / Mice / Animals / Aged / Antagomirs / MicroRNAs:
genetics / Adaptive Immunity / Sepsis: pathology / Adaptive
immunity (Other) / Immunology (Other) / Infectious disease
(Other) / Innate immunity (Other) / Noncoding RNAs (Other) /
Antagomirs (NLM Chemicals) / MicroRNAs (NLM Chemicals) /
MIRN93 microRNA, human (NLM Chemicals)},
cin = {BE01},
ddc = {610},
cid = {I:(DE-He78)BE01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37261908},
pmc = {pmc:PMC10348769},
doi = {10.1172/JCI158348},
url = {https://inrepo02.dkfz.de/record/277773},
}